After 8-month evaluation, the 2020 Venture Top 50 list was finally unveiled. Richland Equities series enterprise Keythera Biopharmaceuticals won the honor on the top 50 New Bud List!

Keythera Biopharmaceuticals is a small molecule innovative drug company which was initially invested by Richland Equities, and introduced into China. The company recently received a Series A financing of nearly 100 million RMB led by Oriza Seed. The founding team has been engaged in research, development, and management in well-known multinational pharmaceutical companies such as Schering Plough and Merck & Co. for a long time. They possess original innovation capabilities of small molecular drugs and rich preclinical and clinical development experience.

Keythera is guided by the international top-level scientific research management principles and focuses on the unmet medical needs of China. The company is committed to developing globally innovative (first in class) and best in class small molecule innovative drugs targeting major diseases such as cancers and autoimmune diseases.  Its goal is to continuously improve the quality of life for patients in China and around the world. In addition to developing its own pipeline of new drug products, Keythera will gradually establish internal drug screening platforms and drug evaluation platforms, aiming to build a solid foundation for the company's long-term innovative capabilities.  

Venture50 (V50) was founded by Zero2IPO Group in 2006 and has since become a benchmark for high-growth enterprise investment. Over the course of more than ten years, it has developed and evolved into a multi-dimensional interactive platform that brings together thousands of entrepreneurial projects, hundreds of investment institutions, and over a thousand investors, with the establishment of the "Wind and Cloud List" and the "New Shoots List" to cater to different stages of enterprise development. Venture50 provides capital assistance to numerous entrepreneurial projects and creates opportunities for interaction between entrepreneurial enterprises and investment institutions.

Back to List